Biocure Technology Inc. (CSE:CURE.X)
Canada
· Delayed Price · Currency is CAD 0.0400
+0.0150 (60.00%)
At close: Apr 14, 2025
Biocure Technology Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2015 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2015 - 2018 |
| Selling, General & Admin | 0.24 | 0.34 | 0.67 | 0.57 | 1.34 | 1.52 | Upgrade
|
| Research & Development | - | - | - | - | 1.56 | 1.42 | Upgrade
|
| Other Operating Expenses | - | - | - | - | 0.01 | - | Upgrade
|
| Operating Expenses | 0.96 | 1.05 | 0.67 | 1.73 | 3.07 | 4.56 | Upgrade
|
| Operating Income | -0.96 | -1.05 | -0.67 | -1.73 | -3.07 | -4.56 | Upgrade
|
| Interest Expense | - | - | - | -0.06 | -0.24 | -0.14 | Upgrade
|
| Interest & Investment Income | - | - | - | - | 0 | 0 | Upgrade
|
| Earnings From Equity Investments | -0.06 | -0.18 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | -0 | -0 | 0.01 | -0.06 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.11 | 0.04 | -0.03 | -0.07 | -0 | -0.04 | Upgrade
|
| EBT Excluding Unusual Items | -0.92 | -1.19 | -0.7 | -1.87 | -3.29 | -4.79 | Upgrade
|
| Gain (Loss) on Sale of Investments | -3.55 | -0.74 | - | - | 0 | -0 | Upgrade
|
| Other Unusual Items | 0.43 | 0.43 | 0.3 | - | 0.21 | - | Upgrade
|
| Pretax Income | -4.03 | -1.49 | -0.4 | -1.87 | -3.08 | -4.79 | Upgrade
|
| Earnings From Continuing Operations | -4.03 | -1.49 | -0.4 | -1.87 | -3.08 | -4.79 | Upgrade
|
| Earnings From Discontinued Operations | -0.04 | -0.35 | -1.11 | 0.72 | - | - | Upgrade
|
| Net Income to Company | -4.06 | -1.84 | -1.52 | -1.15 | -3.08 | -4.79 | Upgrade
|
| Minority Interest in Earnings | 0 | 0.03 | 0.06 | 0.02 | 0.13 | 0.05 | Upgrade
|
| Net Income | -4.06 | -1.81 | -1.45 | -1.13 | -2.95 | -4.74 | Upgrade
|
| Net Income to Common | -4.06 | -1.81 | -1.45 | -1.13 | -2.95 | -4.74 | Upgrade
|
| Shares Outstanding (Basic) | 4 | 10 | 12 | 11 | 11 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 4 | 10 | 12 | 11 | 11 | 11 | Upgrade
|
| Shares Change (YoY) | -94.92% | -13.15% | 3.76% | 4.98% | 1.25% | 1.20% | Upgrade
|
| EPS (Basic) | -1.06 | -0.18 | -0.12 | -0.10 | -0.27 | -0.44 | Upgrade
|
| EPS (Diluted) | -1.06 | -0.18 | -0.12 | -0.10 | -0.27 | -0.44 | Upgrade
|
| Free Cash Flow | 0.07 | -0.22 | -0.83 | -1.08 | -1.31 | -2.68 | Upgrade
|
| Free Cash Flow Per Share | 0.02 | -0.02 | -0.07 | -0.10 | -0.12 | -0.25 | Upgrade
|
| EBITDA | - | - | -0.67 | -1.67 | -3.02 | -4.51 | Upgrade
|
| D&A For EBITDA | - | - | 0.01 | 0.06 | 0.04 | 0.04 | Upgrade
|
| EBIT | -0.96 | -1.05 | -0.67 | -1.73 | -3.07 | -4.56 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.